The Prague.bio international conference will bring together the best of science and business in Prague. Promising ideas will receive money for their development.
Prague, 25 April 2023. The first edition of the Prague.bio international conference will offer a unique meeting of representatives from science and business who will exchange their experiences in the development of new drugs, diagnostics, medical technologies and other areas of biotechnology. The event is supported by the Czech government and will feature renowned experts from the world of BioTech.
The Prague.bio international conference is intended for academics, investors and industry representatives from all over Central Europe. Experienced investors, representatives of leading pharmaceutical as well as diagnostic companies and technology transfer offices will meet promising startups, scientists and students to help them with advice and insights in commercializing their scientific ideas. For industry representatives and investors, the conference will provide an interesting space for exchanging ideas and establishing further cooperation.
"Science and business are often two completely different worlds. But they need each other and have something to offer each other. Scientific projects are often a source of unique commercial ideas and an interesting investment opportunity, while successful commercialisation of scientific knowledge brings significant financial resources back into research," explains Prof. Martin Fusek, Director of IOCB Tech, one of the organisers of the conference. According to him, the Prague.bio conference should contribute to the creation of a permanent network of partners whose goal will be to build a more effective transfer of biotechnology not only in the Czech Republic but also in the entire Central European area.
The transfer is also supported by the government
"Who does not transfer is not a good economist. The transfer of scientific research knowledge into practice is one of the priorities of our government and I am pleased that a conference is being prepared to help this even on an international scale," explains Helena Langšádlová, Minister for Science, Research and Innovation of the Czech Republic, whose department is co-organizing the event. Moreover, according to the Minister, technology transfer is an important topic not only for science but also for the national economy. It can generate billions of Czech crowns in revenue annually.
The Prague conference is based on the experience of similar events abroad. However, it is unique in Central Europe. "At the moment, we can reveal that the Prague.bio conference will not lack lectures by representatives of major pharmaceutical companies, we are also preparing an interesting panel discussion with foreign investors and several pitch sessions that will provide an opportunity to present promising projects in the field of biotechnology," adds Jaromír Zahrádka, CEO of the i&i Biotech Fund and founder of the i&i Prague bio-innovation centre, another of the conference organisers.
The conference will take place on 26 September at Liechtenstein Palace in Prague. Registration is now open for those interested in attending. The relevant form, including payment options, can be found at www.prague.bio. The fee for early registration is 200 Euros, or 150 Euros for students and researchers. Interesting scientific research ideas can also apply for the event and register at the above-mentioned website. The registered projects will be evaluated by an expert committee and the best ones will compete for investor support at the conference.
About IOCB Tech
The Technology Transfer Office IOCB Tech, s.r.o. is a fully owned subsidiary of the Institute of Organic Chemistry and Biochemistry (IOCB). The main responsibilities of IOCB Tech include the identification of commercially interesting projects at IOCB, analysis of their market potential and patentability, protection of intellectual property, support for the development of the projects in the form of project management, search for commercial partners and negotiation of contractual terms for signing license agreements. IOCB Tech has been involved in the process of negotiating and concluding more than a dozen key license agreements with major pharmaceutical partners such as Gilead Sciences, Merck, Novo Nordisk and SHINE Medical Technologies. In 2017, the company established a subsidiary, i&i Prague, which focuses on funding promising early-stage projects at the Institute and other research and academic institutions.
For more information visit www.iocbtech.cz.
About i&i Prague
The i&i Prague Bio-Innovation Center focuses on the transfer of new technologies into practice. The company was established at the Institute of Organic Chemistry and Biochemistry of the CAS and is mainly dedicated to innovations in the field of drug development, diagnostics and medical devices originating from academic institutions. It supports the creation of spin-off companies and the sale of licenses. So far, the company has participated in the creation of or otherwise supported 15 spin-off companies from five countries, has an equity stake in nine of them and has invested over 70 million crowns. In total, the spin-offs in i&i Prague's portfolio have raised more than CZK 1.8 billion from other investors. In addition to direct financial investments, i&i Prague also assists more than 15 research institutions and universities in the Czech Republic and abroad in the commercialization of innovative technologies. In 2021, i&i Prague started up the i&i Bio investment fund.
About i&i Biotech Fund (i&i Bio)
i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €47M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies.
For more information visit www.inibio.eu.
i&i Bio is supported by an investment from the EIF, with the support of:
lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and
the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.